Background Multiple Sclerosis (MS) and Systemic Sclerosis (SSc) are chronic autoimmune diseases that comprise physical and psychological aspects. Disease progression is usually associated with a continuous decline in quality of life. In this devastating scenario, hematopoietic stem cell transplantation (HSCT) has emerged as an alternative treatment, improving physical outcomes and, at the same time, restoring a more normal life. Quality of life evaluations may be used to measure the effects of therapeutic interventions, considering their impact on patient life in the medium and long term.
Objectives To evaluate the impact of HSCT on the Quality of Life (QoL) of SSc (G1) and MS (G2).
Methods In this comparative, longitudinal, cross-sectional study, 56 patients (22 SSc and 34 MS) were included. The Medical Outcomes Study Short-Form 36 (MOS SF-36) scale, used for data collection, mainly assesses the physical health component (PHC) and the mental health component (MHC). The PHC encompasses the following domains: physical functioning (PF), role limitations due to physical problems (RPF), bodily pain (P) and general health perceptions (GHP). The MHC comprises: vitality (VIT), social functioning (SRF), role limitations due to emotional role functioning (ERF) and general mental health (MH). The results of each domain range from 0 to 100, where zero represents the worst and 100 the best state of health. Data were collected at admission and at 2-years after transplantation. Results underwent statistical analysis. Significance levels were established at p<0.05.
In the intragroup analyses, comparing pre and post-HSCT scores, there was general improvement in both disease groups, especially in G2. The intergroup comparisons indicate that before HSCT patients in G1 had better FP than those in G2 (p = 0.03). The other aspects were not significantly different between groups. After HSCT, patients in G2 had a better QoL scores in P (p = 0.4338), GHP (p = 0.0001) and MH (p = 0.0049).
Conclusion These results may be interpreted as positive outcomes of HSCT for MS and SSc. However, our data indicate that HSCT may benefit patients with MS (G2) more than those with SSc (G1).
References  Guimarães FAB, et al. Impact of autologous HSCT on the quality of life of patients with multiple sclerosis. Arquivos de Neuro-Psiquiatria, v. 68, p. 522-527, 2010.
Disclosure of Interests None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.